Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Bases de datos
Tipo de estudio
Tipo del documento
Asunto de la revista
País de afiliación
Intervalo de año de publicación
1.
Mov Disord ; 37(4): 745-757, 2022 04.
Artículo en Inglés | MEDLINE | ID: mdl-34918781

RESUMEN

BACKGROUND: Leucine-rich repeat kinase 2 (LRRK2) is a common risk gene for Parkinson's disease (PD) and inflammatory bowel disorders. However, the penetrance of the most prevalent LRRK2 mutation, G2019S, is <50%. Factors other than genetic mutations are needed in PD process. OBJECTIVES: To examine whether and how gut inflammation may act as an environmental trigger to neurodegeneration in PD. METHODS: A mild and chronic dextran sodium sulfate (DSS)-induced colitis mice model harboring LRRK2 G2019S mutation was established. The colitis severity, immune responses, locomotor function, dopaminergic neuron, and microglia integrity were compared between littermate controls, transgenic LRRK2 wild type (WT), and LRRK2 G2019S mice. RESULTS: The LRRK2 G2019S mice are more vulnerable to DSS-induced colitis than littermate controls or LRRK2 WT animals with increased intestinal expressions of pattern-recognition receptors, including toll-like receptors (TLRs), nuclear factor (NF)-κB activation, and pro-inflammatory cytokines secretion, especially tumor necrosis factor (TNF)-α. Notably, the colonic expression of α-synuclein was significantly increased in LRRK2 G2019S colitis mice. We subsequently observed more aggravated locomotor defect, microglia activation, and dopaminergic neuron loss in LRRK2 G2019S colitis mice than control animals. Treatment with anti-TNF-α monoclonal antibody, adalimumab, abrogated both gut and neuroinflammation, mitigated neurodegeneration, and improved locomotor function in LRRK2 G2019S colitis mice. Finally, we validated increased colonic expressions of LRRK2, TLRs, and NF-κB pathway proteins and elevated plasma TNF-α level in PD patients compared to controls, especially in those with LRRK2 risk variants. CONCLUSIONS: Our findings demonstrate that chronic colitis promotes parkinsonism in genetically susceptible mice and TNF-α plays a detrimental role in the gut-brain axis of PD. © 2021 International Parkinson and Movement Disorder Society.


Asunto(s)
Colitis , Proteína 2 Quinasa Serina-Treonina Rica en Repeticiones de Leucina/metabolismo , Enfermedad de Parkinson , Trastornos Parkinsonianos , Animales , Animales Modificados Genéticamente , Colitis/inducido químicamente , Colitis/complicaciones , Colitis/genética , Humanos , Proteína 2 Quinasa Serina-Treonina Rica en Repeticiones de Leucina/genética , Ratones , Ratones Transgénicos , Mutación/genética , Enfermedad de Parkinson/genética , Enfermedad de Parkinson/metabolismo , Trastornos Parkinsonianos/genética , Inhibidores del Factor de Necrosis Tumoral , Factor de Necrosis Tumoral alfa
3.
Front Cell Neurosci ; 16: 810647, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-35966205

RESUMEN

Dectin-1, a C-type lectin receptor, plays a role in nerve injury in the central nervous system. However, whether it plays a role in the peripheral nervous system is not well understood. Our study showed the expression of Dectin-1 on the membrane of macrophages. We also used a sciatic nerve crushing injury model to demonstrate that there was a delay in nerve degeneration-related processes such as breakdown of injured myelinated nerve fibers and formation of myelin ovoid in groups injected with whole glucan particle soluble (WGPS), a Dectin-1 antagonist. There were also fewer intraneural blood vessels in the Dectin-1 antagonist treated group. Our study suggested inhibiting Dectin-1 delayed debris clearance, nerve degeneration, and angiogenesis after peripheral nerve injury.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA